News
OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe
OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is proud to announce that it is listed as one of the Top 20 MedTech Solution Providers in Europe in 2018 by MedTech Outlook.
Garching n. Munich, Germany, (January 10, 2019) – OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is proud to announce that it is listed as one of the Top 20 MedTech Solution Providers in Europe in 2018 by MedTech Outlook.
The jury consisting of CEOs, CIOs, VCs, industry analysts and MedTech Outlook´s editorial board members selected OncoBeta GmbH and its Rhenium-SCT® therapy as one of the companies that exhibit innovative technologies and strategies. With this award OncoBeta® GmbH belongs to the forefront of providing innovative solutions to solve the increasing complexities in healthcare environments and improve the quality of care. „Being one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer, it is our goal to provide patients and healthcare professionals with the most efficient and innovative therapies possible “, states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH.
View the Top 20 MedTech Solution Providers in Europe under the Digital Magazine Link at: https://www.medicaltechoutlook.com/magazines/December2018/MedTech_Europe/#page=14
Read the Interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH directly at: https://europe.medicaltechoutlook.com/vendor/oncobeta-commercialized-radioisotope-cancer-therapy-cid-210-mid-27.html
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients’ lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.